Revvity(RVTY)

Focus: Revvity is a diagnostics-focused company headquartered in Waltham, MA with 10,000+ employees and $2.8B in FY2025 revenue. The company operates as a mature, profitable public entity in the diagnostics and life science tools space.

Profile data last refreshed 12h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Employees

10001+

Open Jobs

About Revvity

AI assessmentNot Hiring

No open roles listed right now. Follow Revvity to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$2.8B

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

SEC Filings: 2 available

Financials (FY2025)

Help build intelligence for Revvity

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established $2.8B revenue diagnostics leader with strong profitability ($693M net income in FY2025) and stable cash position ($913M)
Engineering-heavy hiring (26 open roles) signals technology modernization and product development momentum
Diversified revenue base across diagnostics reduces single-product dependency and provides career stability

Watch Out For

R&D spend at only 8% of revenue suggests limited pipeline innovation relative to traditional pharma, constraining research career growth
Revenue declined 15% YoY ($3.3B to $2.8B) indicating market pressures or portfolio challenges that may impact long-term stability

Generated by Claude from Revvity's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Revenue

$2.8B17%

R&D Spend

$217M(8%)2%

Net Income

$693M

Cash

$913M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo